Associations - CHEK2 mutation

CHEK2 mutation CHEK2 mutation	Prostate Cancer Prostate Cancer	CHEK2 mutation CHEK2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
CHEK2 mutation CHEK2 mutation	Ovarian Cancer Ovarian Cancer	CHEK2 mutation CHEK2 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
CHEK2 mutation CHEK2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CHEK2 mutation CHEK2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
CHEK2 mutation CHEK2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CHEK2 mutation CHEK2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials	talazoparib Sensitive: C3 – Early Trials
CHEK2 mutation CHEK2 mutation	Breast Cancer Breast Cancer	CHEK2 mutation CHEK2 mutation	Breast Cancer Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials	CDK6 inhibitor Resistant: C3 – Early Trials
CHEK2 mutation CHEK2 mutation	Breast Cancer Breast Cancer	CHEK2 mutation CHEK2 mutation	Breast Cancer Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials	CDK4 inhibitor Resistant: C3 – Early Trials
CHEK2 mutation CHEK2 mutation	Tongue Carcinoma Tongue Carcinoma	CHEK2 mutation CHEK2 mutation	Tongue Carcinoma Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies	ABT-888 + M6620 Sensitive: C4 – Case Studies